AZD3427
Sponsors
AstraZeneca AB, AstraZeneca
Conditions
Heart FailureHeart Failure With Reduced Ejection Fraction (HFrEF)Heart Failure and Pulmonary Hypertension due to Left Heart Disease (WHO Group 2)Heart failure with reduced ejection fractionPulmonary Hypertension (World Health Organization Group 2)Renal ImpairmentRenal impairment
Phase 1
Assessment of Safety, Tolerability, Immunogenicity, and Pharmacokinetics of AZD3427
CompletedNCT04630067
Start: 2020-11-17End: 2022-09-14Updated: 2022-10-20
Study to Evaluate the Effects of AZD3427 in Patients With Heart Failure
WithdrawnNCT04890548
Start: 2021-11-23End: 2022-08-02Updated: 2021-12-17
A Phase 1b, Double-blind, Placebo-controlled, Randomised Trial Investigating the Effect of AZD3427 on Renal Perfusion in HFrEF Patients With Renal Impairment Using Positron Emission Tomography (PET)
CompletedCTIS2024-513143-82-00
Start: 2024-10-15End: 2025-08-21Target: 12Updated: 2025-02-11
AZD3427 Effects on Renal Perfusion in Heart Failure Patients With Reduced Ejection Fraction and Renal Impairment
TerminatedNCT06611423
Start: 2024-10-15End: 2025-08-21Updated: 2025-09-24
Phase 2
A Study of AZD3427 in Participants With Heart Failure and Pulmonary Hypertension Group 2
CompletedNCT05737940
Start: 2023-04-24End: 2025-08-25Updated: 2025-09-24
A Phase IIb Randomised, Double-blind, Placebo-controlled, Multi-centre, Dose-ranging Study of AZD3427 in Participants with Heart Failure and Pulmonary Hypertension due to Left Heart Disease (WHO Group 2)
CompletedCTIS2022-502382-25-00
Start: 2023-08-24End: 2025-08-25Target: 176Updated: 2025-10-02